Advertisement

Planning and Evaluation of Studies on Atherosclerosis in Controlled Clinical Trials

  • Stanley Azen
  • David H. Blankenhorn
  • Sharon Nessim

Abstract

The Cholesterol Lowering Atherosclerosis Study, Phase I (CLAS-I), is a prospective, controlled, angiographic clinical trial designed to evaluate the effectiveness of aggressive cholesterol lowering therapy for the treatment of atherosclerosis. We report here the methodological aspects in planning and evaluating angiographic clinical trials. Consideration is given to choice of the study population, allocation ratios, design of the experiment, and to the evaluation of measurement error and sample sizes. CLAS-I is used to illustrate the points discussed in this paper.

Keywords

Carryover Effect Coronary Angiogram Allocation Ratio Arterial Injection Compliance Score 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    T. C. Chalmers, A. Smith, B. Blackburn, B. Silverman, B. Schroeder, D. Reitman, and A. Ambroz, A method for assessing the quality of a randomized control trial, Controlled Clin. Trials 2: 31 (1981).CrossRefGoogle Scholar
  2. 2.
    R. Peto, M. C. Pike, P. Armitage, N. E. Breslow, D. R. Cox, S. V. Howard, N. Mantel, K. McPherson, J. Peto, and P. G. Smith, Design and analysis of randomized clinical trials requiring prolonged observation of each patient, Br. J. Cancer 34: 585 (1976).CrossRefGoogle Scholar
  3. 3.
    B. W. Brown, The crossover experiment for clinical trials, Biometrics 36: 69 (1980).CrossRefGoogle Scholar
  4. 4.
    M. Hills and P. Armitage, The two-period crossover clinical trial, Br. J. Clin. Pharmacol. 8: 7 (1979).CrossRefGoogle Scholar
  5. 5.
    R. H. Selzer, Atherosclerosis quantitation by computer image analysis, in: “Clinical Diagnosis of Atherosclerosis: Quantitative Methods of Evaluation,” M. G. Bond, W. Insull, S. Glagov, A. B. Chamber and J. F. Cornhill, eds., Springer Verlag, New York (1983).Google Scholar
  6. 6.
    V. S. Hertzberg and L. D. Fisher, A statistical model for interviewer variability in assessing coronary arteriography, presented at the annual meeting of the American Statistical Association, Toronto (1983).Google Scholar
  7. 7.
    D. H. Blankenhorn and S. H. Brooks, Angiographic trials of lipid-lowering therapy, Arteriosclerosis 1: 292 (1981).Google Scholar
  8. 8.
    M. E. Sanmarco, S. H. Brooks and D. H. Blankenhorn, Reproducibility of a consensus panel in the interpretation of coronary angiograms, Am. Heart J. 96: 430 (1978).CrossRefGoogle Scholar
  9. 9.
    W. L. Cashin, S. H. Brooks, D. H. Blankenhorn, et al., Computerized edge tracking and lesion measurement in coronary angiograms. A pilot study comparing smokers with nonsmokers, (in review).Google Scholar
  10. 10.
    J. J. Schlesselman, Planning a longitudinal study: sample size determinations, J. Chron. Dis. 26: 553 (1973).CrossRefGoogle Scholar
  11. 11.
    J. A. Frieman, T. C. Chalmers, H. Smith Jr., and R. R. Keubler, The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial, N. Engl. J. Med. 299: 690 (1978).CrossRefGoogle Scholar
  12. 12.
    A. A. Afifi and S. P. Azen, “Statistical Analysis: A Computer Oriented Approach,” 2nd edition, Academic Press, New York (1979).Google Scholar

Copyright information

© Springer Science+Business Media New York 1984

Authors and Affiliations

  • Stanley Azen
    • 1
  • David H. Blankenhorn
    • 1
  • Sharon Nessim
    • 1
  1. 1.Departments of Preventive Medicine and Medicine, School of MedicineUniversity of Southern CaliforniaLos AngelesUSA

Personalised recommendations